Showing 1311-1320 of 5771 results for "".
- China’s First IGF-1R Monoclonal Antibody Approved, Innovent Biologics Announceshttps://modernod.com/news/chinas-first-igf-1r-monoclonal-antibody-approved-innovent-biologics-announces/2482701/Innovent Biologics announced China’s approval of SYCUME® for thyroid eye disease (TED) earlier this week. SYCUME® is China’s first monoclonal antibody therapeutic option for TED and only the second available globally – marking the first new treatment
- Sydnexis Announces FDA Acceptance of NDA for SYD-101 for the Treatment of Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-fda-acceptance-of-nda-for-syd-101-for-the-treatment-of-progression-of-pediatric-myopia/2482697/Sydnexis announced that the FDA has accepted its new drug application (NDA) for SYD-101, which if approved would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. The FDA assigned a Prescription Drug Use
- Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Developmenthttps://modernod.com/news/harrow-secures-5-year-strategic-agreement-for-triesence-and-announces-next-generation-development/2482696/Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy
- RadiusXR and Glaukos Announce a New Collaboration with Topcon for the Launch of Inspire Visual Field Solutionhttps://modernod.com/news/radiusxr-and-glaukos-announce-a-new-collaboration-with-topcon-for-the-launch-of-inspire-visual-field-solution/2482695/Topcon Healthcare, RadiusXR, and Glaukos announced a new collaboration and the launch of RadiusXR’s new wearable vision testing platform called Inspire. Together, the companies aim to expand access and enable doctors to provide visual field exams and educat
- Nicox Announces New Data from the NCX 470 Mont Blanc Trial, Provides Development Updateshttps://modernod.com/news/nicox-announces-new-data-from-the-ncx-470-mont-blanc-trial-provides-development-updates/2482684/Nicox, an international ophthalmology company, shared new data on their intraocular pressure (IOP)-lowering medication NCX 470 at the 2025 American Glaucoma Society (AGS) Annual Meeting this past weekend. The French company also shared developmental updates from the 470 Mont Blanc phase 3 clinica
- Staar Surgical Announces Leadership Changeshttps://modernod.com/news/staar-surgical-announces-leadership-changes/2482682/Staar Surgical announced that Stephen C. Farrell, current Lead Independent Director of the Staar Board of Directors, has been appointed President and CEO, effective February 26, 2025. He is replacing Tom Frinzi, current President and CEO, who will remain with the company in an advisory role
- Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolaminehttps://modernod.com/news/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution/2482681/Opus Genetics announced completion of enrollment in the VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. Opus also announced that enrollment in the LYNX-2 pivotal phase 3 trial, evaluating phentolamine for the treat
- Glaukos Announces FDA Acceptance of NDA Submission for Epioxahttps://modernod.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa/2482677/Glaukos announced it has received notification from the FDA acknowledging the previously submitted new drug application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus. The FDA stated that the NDA is sufficien
- Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular Hypertensionhttps://modernod.com/news/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma-and-ocular-hypertension/2482669/Alcon announced the full US commercial availability of Voyager DSLT, the first and only direct selective laser trabeculoplasty device (DSLT). According to Alcon, Voyager DSLT may accelerate the adoption of laser as a first-line therapy, making the treatment availabil
- Kala Bio Announces Chief Executive Officer Transitionhttps://modernod.com/news/kala-bio-announces-chief-executive-officer-transition/2482662/Kala Bio announced the resignation of Chief Executive Officer Mark Iwicki, and the appointment of Todd Bazemore, Kala's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of Kala fol